189 related articles for article (PubMed ID: 29898788)
1. Immunomodulatory activities of pixatimod: emerging nonclinical and clinical data, and its potential utility in combination with PD-1 inhibitors.
Hammond E; Haynes NM; Cullinane C; Brennan TV; Bampton D; Handley P; Karoli T; Lanksheer F; Lin L; Yang Y; Dredge K
J Immunother Cancer; 2018 Jun; 6(1):54. PubMed ID: 29898788
[TBL] [Abstract][Full Text] [Related]
2. Heparanase Inhibition by Pixatimod (PG545): Basic Aspects and Future Perspectives.
Hammond E; Dredge K
Adv Exp Med Biol; 2020; 1221():539-565. PubMed ID: 32274726
[TBL] [Abstract][Full Text] [Related]
3. Phase Ib open-label, multicenter study of pixatimod, an activator of TLR9, in combination with nivolumab in subjects with microsatellite-stable metastatic colorectal cancer, metastatic pancreatic ductal adenocarcinoma and other solid tumors.
Lemech C; Dredge K; Bampton D; Hammond E; Clouston A; Waterhouse NJ; Stanley AC; Leveque-El Mouttie L; Chojnowski GM; Haydon A; Pavlakis N; Burge M; Brown MP; Goldstein D
J Immunother Cancer; 2023 Jan; 11(1):. PubMed ID: 36634920
[TBL] [Abstract][Full Text] [Related]
4. A Phase I study of the novel immunomodulatory agent PG545 (pixatimod) in subjects with advanced solid tumours.
Dredge K; Brennan TV; Hammond E; Lickliter JD; Lin L; Bampton D; Handley P; Lankesheer F; Morrish G; Yang Y; Brown MP; Millward M
Br J Cancer; 2018 Apr; 118(8):1035-1041. PubMed ID: 29531325
[TBL] [Abstract][Full Text] [Related]
5. Prior exposure of pancreatic tumors to [sorafenib + vorinostat] enhances the efficacy of an anti-PD-1 antibody.
Booth L; Roberts JL; Poklepovic A; Dent P
Cancer Biol Ther; 2019; 20(1):109-121. PubMed ID: 30142009
[TBL] [Abstract][Full Text] [Related]
6. Immunomodulatory Activities of the Heparan Sulfate Mimetic PG545.
Bendersky V; Yang Y; Brennan TV
Adv Exp Med Biol; 2020; 1221():461-470. PubMed ID: 32274722
[TBL] [Abstract][Full Text] [Related]
7. A phase 1b trial of concurrent immunotherapy and irreversible electroporation in the treatment of locally advanced pancreatic adenocarcinoma.
O'Neill C; Hayat T; Hamm J; Healey M; Zheng Q; Li Y; Martin RCG
Surgery; 2020 Oct; 168(4):610-616. PubMed ID: 32631655
[TBL] [Abstract][Full Text] [Related]
8. PG545, an angiogenesis and heparanase inhibitor, reduces primary tumor growth and metastasis in experimental pancreatic cancer.
Ostapoff KT; Awasthi N; Cenik BK; Hinz S; Dredge K; Schwarz RE; Brekken RA
Mol Cancer Ther; 2013 Jul; 12(7):1190-201. PubMed ID: 23696215
[TBL] [Abstract][Full Text] [Related]
9. Safety and Clinical Response to Combined Immunotherapy with Autologous iNKT Cells and PD-1
Wang J; Cheng X; Jin Y; Xia B; Qin R; Zhang W; Hu H; Mao X; Zhou L; Yan J; Zhang X; Xu J
Cancer Res Commun; 2023 Jun; 3(6):991-1003. PubMed ID: 37377605
[TBL] [Abstract][Full Text] [Related]
10. Mechanisms involved in IL-15 superagonist enhancement of anti-PD-L1 therapy.
Knudson KM; Hicks KC; Alter S; Schlom J; Gameiro SR
J Immunother Cancer; 2019 Mar; 7(1):82. PubMed ID: 30898149
[TBL] [Abstract][Full Text] [Related]
11. IFN-γ down-regulates the PD-1 expression and assist nivolumab in PD-1-blockade effect on CD8+ T-lymphocytes in pancreatic cancer.
Ding G; Shen T; Yan C; Zhang M; Wu Z; Cao L
BMC Cancer; 2019 Nov; 19(1):1053. PubMed ID: 31694582
[TBL] [Abstract][Full Text] [Related]
12. Fostering efficacy of anti-PD-1-treatment: Nivolumab plus radiotherapy in advanced non-small cell lung cancer - study protocol of the FORCE trial.
Bozorgmehr F; Hommertgen A; Krisam J; Lasitschka F; Kuon J; Maenz M; Huber PE; König L; Kieser M; Debus J; Thomas M; Rieken S
BMC Cancer; 2019 Nov; 19(1):1074. PubMed ID: 31703637
[TBL] [Abstract][Full Text] [Related]
13. Nivolumab: A Review in Advanced Melanoma.
Scott LJ
Drugs; 2015 Aug; 75(12):1413-24. PubMed ID: 26220912
[TBL] [Abstract][Full Text] [Related]
14. Phosphatidylserine-targeting antibodies augment the anti-tumorigenic activity of anti-PD-1 therapy by enhancing immune activation and downregulating pro-oncogenic factors induced by T-cell checkpoint inhibition in murine triple-negative breast cancers.
Gray MJ; Gong J; Hatch MM; Nguyen V; Hughes CC; Hutchins JT; Freimark BD
Breast Cancer Res; 2016 May; 18(1):50. PubMed ID: 27169467
[TBL] [Abstract][Full Text] [Related]
15. Cell-intrinsic PD-1 promotes proliferation in pancreatic cancer by targeting CYR61/CTGF via the hippo pathway.
Pu N; Gao S; Yin H; Li JA; Wu W; Fang Y; Zhang L; Rong Y; Xu X; Wang D; Kuang T; Jin D; Yu J; Lou W
Cancer Lett; 2019 Sep; 460():42-53. PubMed ID: 31233838
[TBL] [Abstract][Full Text] [Related]
16. Peritumoral administration of DRibbles-pulsed antigen-presenting cells enhances the antitumor efficacy of anti-GITR and anti-PD-1 antibodies via an antigen presenting independent mechanism.
Patel JM; Cui Z; Wen ZF; Dinh CT; Hu HM
J Immunother Cancer; 2019 Nov; 7(1):311. PubMed ID: 31747946
[TBL] [Abstract][Full Text] [Related]
17. The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.
Mahoney KM; Freeman GJ; McDermott DF
Clin Ther; 2015 Apr; 37(4):764-82. PubMed ID: 25823918
[TBL] [Abstract][Full Text] [Related]
18. Pembrolizumab plus trastuzumab in trastuzumab-resistant, advanced, HER2-positive breast cancer (PANACEA): a single-arm, multicentre, phase 1b-2 trial.
Loi S; Giobbie-Hurder A; Gombos A; Bachelot T; Hui R; Curigliano G; Campone M; Biganzoli L; Bonnefoi H; Jerusalem G; Bartsch R; Rabaglio-Poretti M; Kammler R; Maibach R; Smyth MJ; Di Leo A; Colleoni M; Viale G; Regan MM; André F;
Lancet Oncol; 2019 Mar; 20(3):371-382. PubMed ID: 30765258
[TBL] [Abstract][Full Text] [Related]
19. Safety evaluation of nivolumab added concurrently to radiotherapy in a standard first line chemo-radiotherapy regimen in stage III non-small cell lung cancer-The ETOP NICOLAS trial.
Peters S; Felip E; Dafni U; Belka C; Guckenberger M; Irigoyen A; Nadal E; Becker A; Vees H; Pless M; Martinez-Marti A; Tufman A; Lambrecht M; Andratschke N; Piguet AC; Kassapian M; Roschitzki-Voser H; Rabaglio-Poretti M; Stahel RA; Vansteenkiste J; De Ruysscher D
Lung Cancer; 2019 Jul; 133():83-87. PubMed ID: 31200833
[TBL] [Abstract][Full Text] [Related]
20. Radiochemotherapy combined with NK cell transfer followed by second-line PD-1 inhibition in a patient with NSCLC stage IIIb inducing long-term tumor control: a case study.
Kokowski K; Stangl S; Seier S; Hildebrandt M; Vaupel P; Multhoff G
Strahlenther Onkol; 2019 Apr; 195(4):352-361. PubMed ID: 30747241
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
